SciPharm Trading DMCC

Who we are

Scipharm in UAE was established in 2021 with the vision to Elevate the options for precision medicine with the highest quality services in the molecular medicine sector, offering comprehensive tumor profiling for targeted therapies.

Scipharm was inspired and guided for this mission by creating a partnership with one of the best 17 laboratories word wide in molecular medicine quality assurance Genekor, (mentioned Gen.Med.2018) .

Genekor is developing highly sensitive and specific molecular assays that are applicable in everyday clinical practice.

With our partners and our experienced personnel in the medical field, we share the same goals to provide and assist physicians in applying cutting edge technologies for individualized medicine at affordable prices.

The clinical expertise of Genekor focuses on:
  • Response to Targeted Therapy
  • Pharmacogenetics
  • Determination of Hereditary Cancer, cardiovascular Diseases and Neurological Disorders
  • New Unique Technological Platforms (OncotypeDX BreastTM, HerediGENETM, PrIMeTM, Cordis DXTM, Cerebrum DX TM, PCA3TM)

The specialized laboratories of GeneKor Medical S.A. are accredited by the Hellenic Accreditation Systems S.A (ESYD) under the terms of the ELOT EN ISO 15189:2012 (Cert. No. 822) and Certified with ISO 9001:2015 (Cert. No. 041150049) and ELOT ISO/IEC 27001:2013 (Cert.No 048190009) by TUV NORD HELLAS.

GeneKor is staffed by board certified internationally recognized and published scientists and doctors who are able to provide analysis and recommendations to physicians and their patients. Therefore, GeneKor is in position to carry out all existing molecular biology assays. GeneKor offers to the treating physicians of various specialties tools to individualize their patients’ treatment needs.

At GeneKor, we are devoted at offering services of the highest quality, by constantly monitoring the scientific developments in the health sector, updating our laboratory equipment and maximizing our levels of accuracy and reliability.

GeneKor is actively establishing its international presence with an ultimate goal to extend its collaborations in more countries. Our strategic goal is the constant incorporation of new technology platforms and assays in order to always provide the most up-to-date, reliable and cutting edge tools to the treating physicians.


The Management and the Scientific Team of GeneKor Medical laboratories are focused on providing the highest quality of Molecular Services.

  • The specialized laboratories of GeneKor Medical S.A.  are accredited by the Hellenic Accreditation Systems S.A (ESYD) under the terms of the ELOT EN ISO 15189:2012 (Cert. No. 822).
  • Certified with ELOT EN ISO 9001:2015 (Cert. No. 041150049) and ELOT ISO/IEC 27001:2013 (Cert.No 048190009) by TUV NORD HELLAS.
  • Our services are assured by participating in proficiency testing (PT) programs by:
    • CAP (College of American Pathologists).
    • External Quality Assurance EMQN (European Molecular and Genetics Quality Network).
    • UKNEQAS –ICC & ISH (United Kingdom National External Quality Assessment Services, Immunohistochemistry & In-situ Hybridization).
    • GenQA (Genomics Quality Assessment).

Genekor is certified by external quality assessment for the following tests:

  1. Mutation analysis in BRCA1 & BRCA2 genes (Breast Cancer susceptibility genes 1 and 2) – EMQN & CAP
  2. Somatic mutation analysis (EGFR, BRAF, KRAS, KIT, NRAS, HRAS & PDGFRA gene) – CAP, EMQN & GenQA
  3. Analysis of DNA Microsatellite Instability (MSI) – GenQA
  4. Detection and quantification of the ALK gene rearrangements – UKNEQAS (ICC&ISH)
  5. Detection and quantification of the overexpression of the HER2/neu gene – UKNEQAS (ICC&ISH)